34 Results for "

systemic sclerosis

" in MedChemExpress (MCE) Product Catalog:
Products (34)

34 Results for "systemic sclerosis" in MCE Product Catalog:

7
7 Publications Verification
Cat. No.: HY-100113
CAS No.: 477775-14-7
Purity:  99.02%
Synonyms: AT2 receptor agonist C21
Buloxibutid (AT2 receptor agonist C21) is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a Ki value of 0.4 nM for porcine AT2R. Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase MMP-13) and tissue repair mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-B1028
CAS No.: 16816-67-4
Synonyms: D-Pantethine; LBF disulfide
Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-150298
CAS No.: 2226636-04-8
Purity:  99.71%
Synonyms: CPI-818
Target:  

Itk

Research Areas:  

Inflammation/Immunology Cancer

Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8 + cells that possess enhanced T effector function .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18620
CAS No.: 33231-14-0
DZ2002 is an orally active, reversible and low-cytotoxic type III SAHH inhibitor (Ki=17.9 nM), with good immunosuppressive activity. DZ2002 prevents the development of experimental dermal fibrosis by reversing the profibrotic phenotype of various cell types. DZ2002 can be used in studies of autoimmune diseases such as lupus syndrome and systemic sclerosis .
loading...
    loading...
Cat. No.: HY-14930
CAS No.: 862189-95-5
Purity:  99.70%
Synonyms: SK3530
Mirodenafil (SK3530) is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil is a glucocorticoid receptor (GR) modulator Mirodenafil activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .
loading...
    loading...
Cat. No.: HY-156438
CAS No.: 2272917-13-0
Purity:  99.65%
Synonyms: NT-0796
Ruvonoflast (NT-0796) is an orally active, selective and CNS-penetrant NLRP3 inflammasome inhibitor. Ruvonoflast inhibits IL-1β release in human PBMC cells with an IC50 value of 0.32 nM. Ruvonoflast is an isopropyl ester that undergoes intracellular conversion to Ruvonoflast, the carboxylic acid active species. Ruvonoflast reverses high fat diet-induced obesity, systemic inflammation and astrogliosis in the diet-induced obesity mouse model. Ruvonoflast is promising for research of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis .
loading...
    loading...
Cat. No.: HY-14930A
CAS No.: 862189-96-6
Purity:  99.85%
Synonyms: SK-3530 dihydrochloride
Mirodenafil (SK3530) dihydrochloride is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil dihydrochloride is a glucocorticoid receptor (GR) modulator Mirodenafil dihydrochloride activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil dihydrochloride can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .
loading...
    loading...
Cat. No.: HY-P991267

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

CAN10 is is a humanized monoclonal antibody inhibitor targeting interleukin 1RAP (IL1RAP). CAN10 blocks IL-1, IL-33, and IL-36 signalling by targeting IL1RAP, preventing downstream proinflammatory and profibrotic responses. CAN10 reduces dermal and pulmonary fibrosis. CAN10 can be used for the research of immune system diseases, such as systemic sclerosis .
loading...
    loading...
Cat. No.: HY-175739
CAS No.: 932992-44-4
TFAM activator 1 is a TFAM activator. TFAM activator 1 increases TFAM protein levels, promotes mitochondrial DNA stability, increases mitochondrial DNA copy number, and prevents mitochondrial DNA from escaping into the cytoplasm. TFAM activator 1 improves cellular energy metabolism in cybrid cells. TFAM activator 1 reduces fibrosis markers in fibroblasts. TFAM activator 1 can be used in the research of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome, systemic sclerosis, and autoimmune diseases .
loading...
    loading...
Cat. No.: HY-P99325
CAS No.: 252662-47-8
Synonyms: IDEC-131; Anti-Human CD40 ligand Recombinant Antibody

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
loading...
    loading...
Cat. No.: HY-P991363
Target:  

Myosin STAT

Research Areas:  

Inflammation/Immunology

AX-202 is a humanized anti-S100A4 monoclonal antibody that neutralizes S100A4. AX-202 blocks downstream profibrotic and proinflammatory effects. AX-202 exerts antifibrotic effects in skin fibrosis. AX-202 induces regression of pre-established skin fibrosis. AX-202 modulates anti-inflammatory and antifibrotic transcriptional pathways. AX-202 inhibits STAT3 phosphorylation. AX-202 induces AMPK and CASQ1 expression. AX-202 modulates SSc-related transcriptional signatures. AX-202 reduces tenascin-C, a DAMP and endogenous TLR4 ligand. AX-202 can be used for the research of systemic sclerosis .
loading...
    loading...
Cat. No.: HY-135304
CAS No.: 2304852-21-7
Purity:  99.29%
PAD-IN-2 is a potent pad4 inhibitor (IC50: <1 μM). PAD-IN-2 can be used in the research of auto-immune diseases and cancers, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cystic fibrosis, asthma, multiple sclerosis and psoriasis .
loading...
    loading...
Cat. No.: HY-P99883
CAS No.: 1399584-78-1
Synonyms: SAR156597
Romilkimab (SAR156597) is a humanized IG antibody that specifically targets IL-4 and IL-13. Romilkimab can be used for the research of diffuse cutaneous systemic sclerosis .
loading...
    loading...
Cat. No.: HY-P99226
CAS No.: 2245966-28-1
Synonyms: MEDI7734; VIB7734
Daxdilimab (MEDI7734; VIB7734) is a monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7) that depletes plasmacytoid dendritic cells and reduces IFN1 production by binding to the plasmacytoid dendritic cell-specific surface molecule ILT7 and recruiting effector natural killer cells. Daxdilimab (MEDI7734; VIB7734) can be used for research on systemic lupus erythematosus, systemic sclerosis, and polymyositis .
loading...
    loading...
Cat. No.: HY-P2940
CAS No.: 9032-65-9
Target:  

NAMPT

Research Areas:  

Inflammation/Immunology

NADase is an ectoenzyme/membrane-bound enzyme targeting nicotinamide adenine dinucleotide (NAD +). NADase regulates intracellular NAD + homeostasis by hydrolyzing NAD + into nicotinamide mononucleotide (NMN) and ADP-ribose. NADase is promising for research of autoimmune diseases (e.g., systemic sclerosis, systemic lupus erythematosus) and aging-related disorders .
loading...
    loading...
Cat. No.: HY-P991051

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

GSK-2330811 is a humanized IgG1 antibody that targets Oncostatin M (OSM). GSK-2330811 has the potential for the study of diffuse cutaneous systemic sclerosis (dcSSc). The isotype control for GSK-2330811 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-P991351

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. RTX-002 can be used to study autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis .
loading...
    loading...
Cat. No.: HY-B1028R
CAS No.: 16816-67-4
Synonyms: D-Pantethine (Standard); LBF disulfide (Standard)
Pantethine (Standard) is the analytical standard of Pantethine. This product is intended for research and analytical applications. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .
loading...
    loading...
Cat. No.: HY-14930R
CAS No.: 862189-95-5
Synonyms: SK3530 (Standard)
Mirodenafil (Standard) is the analytical standard of Mirodenafil. This product is intended for research and analytical applications. Mirodenafil (SK3530) is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil is a glucocorticoid receptor (GR) modulator Mirodenafil activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .
loading...
    loading...
Cat. No.: HY-142698
CAS No.: 2735713-77-4
Target:  

Guanylate Cyclase

Research Areas:  

Cardiovascular Disease

SGC agonist 2 is a potent agonist of soluble guanylate cyclase (SGC). Soluble guanylate cyclase is a key signal transduction enzyme in the NO-sGC-cGMP signaling pathway. SGC agonist 2 has the potential for the research of cardiovascular disease (heart failure, pulmonary hypertension, angina, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis) (extracted from patent WO2021219088A1, compound 031) .
loading...
    loading...